The House voted to repeal the Cadillac tax, which, after being delayed twice, was expected to go into effect in 2022; provisional data releaased by the CDC indicate that drug overdose rates have dropped for the first time in 3 decades; the Center for Science in the Public Interest filed comments with the FDA urging it to take a more active role in regulating marijuana.
The House on Wednesday voted to repeal the High-Cost Plan Tax, also known as the Cadillac tax, which would target high-cost health plans offered by employers to try and limit unnecessary healthcare utilization and control healthcare spending. With opposition from both sides of the aisle, the tax was voted down 419-6, reported The Hill. After being delayed twice, the tax was slated to go into effect in 2022. According to the Congressional Budget Office, repealing the tax will cost the government $196.9 billion over 10 years. It’s unclear whether the Senate will also vote on the measure.
For the first time since 1990, drug overdose death rates have dropped, according to the latest provisional data released by the CDC. Between the 12-month period ending December 2017 and the 12-month period ending 2018, there was a 5.1% decline in overdose death rates. There were nearly 68,000 overdose death rates in the 12-month period ending December 2018, compared with approximately 72,000 in the 12-month period ending December 2017. Last month, provisional data offered cautious optimism that rates were expected to drop for the first time in 3 decades. Since the 1990s, drug overdoses have killed approximately 870,000 people.
The Center for Science in the Public Interest this week filed comments with the FDA calling on the agency to take a more active role in regulating consumer use of marijuana, arguing that current state legalization approaches combined with a lack of clarity around the federal role will fail to protect consumers. “Decriminalization and legalization of cannabis is occurring at the state level, producing a legal patchwork with inadequate policies and funding to protect consumers,” the center wrote, adding that it is crucial that the FDA asserts its authority to ensure that products are safe, accurately labeled, and free of contaminants, and that consumers are aware of relevant risks.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More